Drs. Andrea Cedeno and Kim A. Carmichael recently published their article in Endocrinology Consultant titled, “What You Need to Know About SGLT2 Inhibitors” SGLT2i are widely used in the clinical treatment of type 2 diabetes mellitus (T2DM). SGLT2i reduce blood glucose, and protect the heart and kidney, which can significantly reduce cardiovascular events, delay the progression of renal failure, and improve the quality of life for patients.
In their article, the authors state, “It is critical to improve the health of patients at risk of developing end-stage renal disease (ESRD) with the tools available.”
The article covers how SGLT2i work; the cardiovascular and renal benefits associated with SGLT2i; the risks associated with SGLT2i; when not to use a SGLT2i; and can SGLT2i be safely combined with other medications.